Botanical species · safety record

Dipsacus inermis

The EFSA Compendium of Botanicals holds 6 constituent measurements and 2 adverse-effect records for Dipsacus inermis. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Dipsacus inermis Wall.

6Constituent measurements

2Safety records

6Cited sources

0Licensed products (Canada)

Also recorded as

Dipsacus asper Wall. ex DC.
Dipsacus asperoidis C. Y. Cheng & T. M. Ai

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Lignans	Roots and other underground parts	Solvent extraction	—	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Saponins	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
3,4-dihydroxybenzoic acid	Unspecified	Solvent extraction	—	Unspecified	No resolvable identifier
Pyridine alkaloids	Roots and other underground parts	Solvent extraction	—	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Saponins	Unspecified	Solvent extraction	≥ 2.2 Percent	UV/VIS spectroscopy (photometry)	No resolvable identifier
Saponins	Unspecified	Solvent extraction	≤ 19.9 Percent	UV/VIS spectroscopy (photometry)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Teratogenic	Bone (deprecated)	Roots and other underground parts	Solvent extraction	House mouse (as animal)	Reproduction toxicity	Resolve DOI
Teratogenic	Bone (deprecated)	Roots and other underground parts	Solvent extraction	House mouse (as animal)	Reproduction toxicity	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Hung, TM., Jin, W., Thuong, PT., Song, KS., Seong, YH., Bae, K. Cytotoxic saponins from the root of Dipsacus asper Wall. Archives of pharmacal research, 2005, vol. 28, no. 9, p. 1053-1056. DOI
Liu, Yong., Wei, Yingfang., Yan, Jie., Guo, Shanshan., Wang, Huadong., Xie, Dawen. Determination of total saponin content in Dipsacus asper from different areas. Shizhen guoyi guoyao, 2009, p. 2767-2768.
Li, Feng., Tanaka, Ken., Watanabe, Shiro., Tezuka, Yasuhiro., Saiki, Ikuo. Dipasperoside A, a Novel Pyridine Alkaloid-Coupled Iridoid Glucoside from the Roots of Dipsacus asper . Chemical & pharmaceutical bulletin, 2013, vol. 61, no. 12, p. 1318-1322.
Xiao, Ting Ting., Xu, Min., Yang, Xiao Hong., Kok, Lam., Chow, Yeuk Lung., Zhao, Zhong Zhen., Leung, Kelvin Sze-Yin., Yang, Zhi Jun., Tian, Xiao Ying., Li, Zhi., Xin, Meng Yun., Xu, Wei. The evaluation on embryotoxicity of Dipsaci Radix with mice and embryonic stem cells . Journal of ethnopharmacology, 2014, vol. 151, no. 1, p. 114-122. DOI
Kim, Soon Young., Kwon, Yong Soo., Kim, Chang Min. Chemical constituents from Dipsacus asper. Saengyak hakhoechi, 1999, p. 420-422.
Sun, Xinguang., Ma, Guoxu., Zhang, Dawei., Huang, Wenhua., Ding, Gang., Hu, Huagang., Tu, Guangzhong., Guo, Baolin. New Lignans and Iridoid Glycosides from Dipsacus asper Wall. Molecules, 2015, vol. 20, no. 2, p. 2165-2175. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature